Page last updated: 2024-08-23

dihydro-beta-erythroidine and sazetidine-a

dihydro-beta-erythroidine has been researched along with sazetidine-a in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Caldarone, BJ; Eaton, JB; Kozikowski, AP; Lukas, RJ; Yu, LF; Zhang, HK1
DeCuir, D; Gordon, CJ; Kellar, KJ; Levin, ED; Rezvani, AH; Sexton, HG; Timofeeva, O; Xiao, Y1
Cann, C; Gould, TJ; Kutlu, MG; Tumolo, JM1

Reviews

1 review(s) available for dihydro-beta-erythroidine and sazetidine-a

ArticleYear
Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.
    Journal of medicinal chemistry, 2014, Oct-23, Volume: 57, Issue:20

    Topics: Alkaloids; Antidepressive Agents; Azetidines; Azocines; Depression; Humans; Ligands; Molecular Targeted Therapy; Nicotinic Agonists; Nicotinic Antagonists; Quinolizines; Receptors, Nicotinic

2014

Other Studies

2 other study(ies) available for dihydro-beta-erythroidine and sazetidine-a

ArticleYear
Effects of sazetidine-A, a selective α4β2* nicotinic receptor desensitizing agent, on body temperature regulation in mice and rats.
    European journal of pharmacology, 2012, May-05, Volume: 682, Issue:1-3

    Topics: Aconitine; Animals; Azetidines; Body Temperature Regulation; Dihydro-beta-Erythroidine; Dose-Response Relationship, Drug; Drug Interactions; Male; Mice; Nicotine; Nicotinic Antagonists; Pyridines; Rats; Receptors, Nicotinic

2012
Differential effects of α4β2 nicotinic receptor antagonists and partial-agonists on contextual fear extinction in male C57BL/6 mice.
    Psychopharmacology, 2018, Volume: 235, Issue:4

    Topics: Animals; Anxiety; Azetidines; Dihydro-beta-Erythroidine; Disease Models, Animal; Extinction, Psychological; Fear; Male; Mice; Mice, Inbred C57BL; Nicotinic Agonists; Nicotinic Antagonists; Pyridines; Receptors, Nicotinic; Stress Disorders, Post-Traumatic; Varenicline

2018